Compare DGICB & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DGICB | DCTH |
|---|---|---|
| Founded | 1986 | 1988 |
| Country | United States | United States |
| Employees | 851 | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 576.5M | 578.4M |
| IPO Year | 1995 | 2015 |
| Metric | DGICB | DCTH |
|---|---|---|
| Price | $15.80 | $15.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 1.7K | ★ 289.8K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.34% | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $978,014,322.00 | N/A |
| Revenue This Year | $2.26 | $24.54 |
| Revenue Next Year | N/A | $33.15 |
| P/E Ratio | ★ $8.06 | $392.25 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.87 | $8.12 |
| 52 Week High | $29.99 | $17.42 |
| Indicator | DGICB | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 31.71 | 45.99 |
| Support Level | $15.00 | $15.68 |
| Resistance Level | $17.93 | $16.51 |
| Average True Range (ATR) | 1.01 | 0.45 |
| MACD | -0.76 | -0.13 |
| Stochastic Oscillator | 3.40 | 27.43 |
Donegal Group Inc is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty insurance in 21 Mid-Atlantic, Midwestern, Southern, and Southwestern states. It includes three segments: Investments Function, Commercial Lines of Insurance, and Personal Lines of Insurance. The majority of revenue is from the commercial Lines segment. The commercial Lines segment consists mainly of commercial automobile, commercial multi-peril, and workers' compensation policies.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.